Skip to Content
Søk Menu

Nivolumab in combination with ipilimumab as first-line treatment of patients with NSCLC continues to show an improved overall survival

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Implementation of Early Specialized Palliative Care in an Oncologic Department

/ Katrine Rahbek Schønnemann / Sabine Ute Alice Gill
Kreft
Petter Brandal

Insights from Onkologisk Forum 2023

/ Petter Brandal
KreftOnkologiskForum23 Play the Video 5:16
Bettina Kulle Andreassen

The Value of Real-World Data in Clinical Oncological Research

/ Bettina Kulle Andreassen
KreftOnkologiskForum23 Play the Video 3:02
Petter Brandal

Proton vs Photon Radiotherapy for Brain Tumors in Patients with Diffuse Grade 2 and 3 Gliomas

/ Petter Brandal
KreftOnkologiskForum23 Play the Video 3:02
Kenneth Jensen

Proton Therapy for Head and Neck Cancer

/ Kenneth Jensen
KreftOnkologiskForum23 Play the Video 4:11
Giuseppe Curigliano

Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer Treatment

/ Giuseppe Curigliano
BrystkreftKreft Play the Video 4:28
Rasmus Westermann

Cancer Risk in Rheumatoid Arthritis Patients Treated with Non-TNFi bDMARDs

/ Rasmus Westermann
KreftRevmatoid artrittSCR23 Play the Video 7:28

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunterapiLungekreftNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
LungekreftNSCLCWCLC23
Back to top